Table 5. The associations between the gene polymorphisms and clinical characteristics of cervical cancer patients.

SNP	clinical stages				subtype
	I- II		III- IV		Squamous carcinomas		adenocarcinoma
	OR (95%CI)	p			OR (95%CI)	p	OR (95%CI)	p
rs1048512	0.57 (0.34–0.96)	0.033	1.38 (0.85–2.24)	0.194	0.88 (0.59–1.31)	0.536	0.53 (0.07–4.06)	0.532
rs6659346	0.60 (0.36–0.99)	0.044	1.54 (0.97–2.45)	0.066	0.96 (0.65–1.4)	0.818	0.5 (0.07–3.85)	0.498
rs11006369	1.47 (0.95–2.28)	0.085	1.2 (0.7–2.07)	0.502	1.32 (0.89–1.96)	0.167	2.25 (0.62–8.15)	0.205
rs2862833	1.01 (0.77–1.34)	0.920	1.45 (1.04–2.03)	0.028	1.12 (0.87–1.42)	0.381	2.62 (0.9–7.65)	0.067
rs3741216	0.71 (0.39–1.29)	0.263	1.55 (0.89–2.72)	0.122	1.02 (0.64–1.63)	0.920	1.8 (0.39–8.17)	0.442
rs217727	1.81 (1.33–2.46)	0.000	1.23 (0.84–1.8)	0.289	1.55 (1.18–2.04)	0.002	1.11 (0.35–3.51)	0.856
rs2839702	0.86 (0.64–1.15)	0.308	0.86 (0.61–1.22)	0.409	0.88 (0.69–1.14)	0.331	0.96 (0.34–2.68)	0.940
rs2067051	0.76 (0.56–1.03)	0.073	0.92 (0.65–1.3)	0.623	0.84 (0.65–1.08)	0.170	1 (0.36–2.78)	0.994
rs2274062	0.77 (0.58–1.02)	0.067	0.99 (0.71–1.38)	0.930	0.83 (0.65–1.06)	0.134	1.01 (0.37–2.72)	0.989
rs9318375	0.98 (0.54–1.80)	0.959	0.37 (0.13–1.05)	0.051	0.71 (0.4–1.26)	0.237	1.08 (0.14–8.47)	0.938
rs2732044	1.10 (0.83–1.46)	0.494	0.7 (0.5–0.99)	0.043	0.93 (0.73–1.19)	0.571	1.26 (0.47–3.41)	0.646
rs1030389	1.04 (0.79–1.38)	0.783	0.68 (0.48–0.96)	0.028	0.89 (0.7–1.13)	0.341	1.14 (0.42–3.09)	0.792
rs1045935	1.07 (0.81–1.42)	0.627	0.6 (0.43–0.85)	0.004	0.79 (0.62–1)	0.053	0.63 (0.23–1.77)	0.381
rs12902710	1.25 (0.94–1.65)	0.121	1.02 (0.73–1.43)	0.895	1.15 (0.9–1.46)	0.267	1.95 (0.7–5.42)	0.196
rs9931702	0.68 (0.50–0.93)	0.015	0.87 (0.61–1.24)	0.441	0.75 (0.57–0.97)	0.029	0.28 (0.06–1.24)	0.074
rs9302648	0.68 (0.50–0.93)	0.015	0.85 (0.59–1.21)	0.363	0.74 (0.57–0.96)	0.024	0.28 (0.06–1.24)	0.074

CI, confidence interval; ORs, odds ratios; p-value ≤ 0.05 indicates statistical significance.